

BIOLIFE SOLUTIONS INC  
Form 10-Q  
November 08, 2018

Table of Contents

---

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

---

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE  
ACT OF 1934**

For the quarterly period ended September 30, 2018

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE  
ACT OF 1934**

For the transition period from to

Commission File Number 001-36362

---

**BioLife Solutions, Inc.**

*(Exact name of registrant as specified in its charter)*

**DELAWARE**

**94-3076866**

*(State or other jurisdiction of (IRS Employer*

*incorporation or organization) Identification No.)*

**3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL, WASHINGTON, 98021**

*(Address of registrant's principal executive offices, Zip Code)*

**(425) 402-1400**

*(Telephone number, including area code)*

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes      No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (S232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit said files). Yes      No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer      Accelerated filer      Non-accelerated filer      Smaller reporting company

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes      No

As of November 7, 2018, 18,499,767 shares of the registrant's common stock were outstanding.

---

---

1

---

Table of Contents

**BIOLIFE SOLUTIONS, INC.**

**FORM 10-Q**

**FOR THE QUARTER ENDED SEPTEMBER 30, 2018**

**TABLE OF CONTENTS**

**PART I. FINANCIAL INFORMATION**

Item 1. Financial Statements

Balance Sheets as of September 30, 2018 (unaudited) and December 31, 2017 3

Statements of Operations (unaudited) for the three and nine month periods ended September 30, 2018 and 2017 4

Statements of Cash Flows (unaudited) for the nine month periods ended September 30, 2018 and 2017 5

Statements of Shareholders' Equity (unaudited) for the nine months ended September 30, 2018 6

Notes to Financial Statements (unaudited) 7

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 15

Item 3. Quantitative and Qualitative Disclosures about Market Risk 20

Item 4. Controls and Procedures 20

**PART II. OTHER INFORMATION**

Item 6. Exhibits 20

Index to Exhibits 21

Signatures 22



Table of Contents**PART I. FINANCIAL INFORMATION****Item 1. Financial Statements****BioLife Solutions, Inc.****Balance Sheets****(Unaudited)**

	<b>September 30, 2018</b>	<b>December 31, 2017</b>
Assets		
Current assets		
Cash and cash equivalents	\$32,380,674	\$6,663,318
Accounts receivable, trade, net of allowance for doubtful accounts of \$0 and \$5,575 at September 30, 2018 and December 31, 2017, respectively	2,699,342	1,021,315
Inventories	2,910,927	1,846,746
Prepaid expenses and other current assets	298,005	399,502
Total current assets	38,288,948	9,930,881
Property and equipment		
Leasehold improvements	1,284,491	1,284,491
Furniture and computer equipment	705,948	682,466
Manufacturing and other equipment	1,510,729	1,148,006
Subtotal	3,501,168	3,114,963
Less: Accumulated depreciation	(2,234,286 )	(2,008,927 )
Net property and equipment	1,266,882	1,106,036
Investment in SAVSU	6,856,980	1,070,120
Long term deposits	36,166	36,166
Total assets	\$46,448,976	\$12,143,203
Liabilities and Shareholders' Equity		
Current liabilities		
Accounts payable	\$1,089,553	\$690,702
Accrued expenses and other current liabilities	162,981	200,548
Accrued compensation	712,615	491,432
Deferred rent	130,216	130,216
Total current liabilities	2,095,365	1,512,898
Deferred rent, long-term	386,113	492,207
Other long-term liabilities	37,855	45,512
Total liabilities	2,519,333	2,050,617

Commitments and contingencies (Note 9)

Shareholders' equity

Preferred stock, \$0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 3,187 and 4,250 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	3	4
Common stock, \$0.001 par value; 150,000,000 shares authorized, 18,237,425 and 14,021,422 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	18,237	14,021
Additional paid-in capital	115,775,040	84,036,444
Accumulated deficit	(71,863,637 )	(73,957,883 )
Total shareholders' equity	43,929,643	10,092,586
Total liabilities and shareholders' equity	\$46,448,976	\$12,143,203

The accompanying Notes to Financial Statements are an integral part of these financial statements

Table of Contents**BioLife Solutions, Inc.****Statements of Operations****(unaudited)**

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2018</b>	<b>2017</b>	<b>2018</b>	<b>2017</b>
Product sales	\$5,293,075	\$2,963,411	\$14,285,811	\$7,887,377
Cost of product sales	1,606,303	1,095,724	4,506,911	2,980,965
Gross profit	3,686,772	1,867,687	9,778,900	4,906,412
Operating expenses				
Research and development	312,000	293,093	983,066	898,451
Sales and marketing	725,201	488,688	1,977,871	1,547,087
General and administrative	1,454,573	1,118,251	4,198,474	3,298,461
Total operating expenses	2,491,774	1,900,032	7,159,411	5,743,999
Operating income (loss)	1,194,998	(32,345 )	2,619,489	(837,587 )
Other income (expenses), net				
Interest income	79,773	103	120,728	227
Interest expense	(1,313 )	(1,077 )	(3,545 )	(188,992 )
Write-off of deferred financing costs	—	(67,664 )	—	(67,664 )
Amortization of debt discount	—	—	—	(155,996 )
Loss from equity-method investment in SAVSU	(42,689 )	(217,735 )	(363,243 )	(707,208 )
Total other income (expenses), net	35,771	(286,373 )	(246,060 )	(1,119,633 )
Net income (loss) before provision for income taxes	1,230,769	(318,718 )	2,373,429	(1,957,220 )
Income taxes	—	—	—	—
Net income (loss) after provision for income taxes	1,230,769	(318,718 )	2,373,429	(1,957,220 )
Less: Preferred stock dividends	(79,675 )	(106,250 )	(279,183 )	(106,250 )
Net income (loss) attributable to common stockholders	\$1,151,094	\$(424,968 )	\$2,094,246	\$(2,063,470 )
Basic net income (loss) per common share	\$0.07	\$(0.03 )	\$0.13	\$(0.16 )
Diluted net income (loss) per common share	\$0.05	\$(0.03 )	\$0.10	\$(0.16 )
Weighted average shares outstanding used to compute basic earnings per share	17,273,412	13,238,248	15,529,026	13,102,238
Weighted average shares outstanding used to compute diluted earnings per share	23,656,633	13,238,248	21,051,219	13,102,238

The accompanying Notes to Financial Statements are an integral part of these financial statements





Table of Contents**BioLife Solutions, Inc.****Statements of Cash Flows****(unaudited)**

	<b>Nine Months Ended September 30,</b>	
	<b>2018</b>	<b>2017</b>
Cash flows from operating activities		
Net income (loss)	\$2,373,429	\$(1,957,220)
Adjustments to reconcile net income (loss) to net cash used in operating activities		
Depreciation	244,927	259,895
Stock-based compensation expense	1,130,945	957,711
Stock issued for services	—	71,250
Write-off of deferred financing costs	—	67,664
Amortization of deferred rent related to lease incentives	(95,248 )	(95,249 )
Amortization of debt discount	—	155,996
Loss from equity-method investment in SAVSU	363,243	707,208
Change in operating assets and liabilities		
(Increase) Decrease in		
Accounts receivable, trade	(1,678,027 )	(159,851 )
Inventories	(1,064,181 )	(103,274 )
Prepaid expenses and other current assets	(48,606 )	(101,479 )
Increase (Decrease) in		
Accounts payable	342,875	(227,732 )
Accrued compensation and other current liabilities	204,653	138,885
Accrued interest	—	152,143
Deferred rent	(11,490 )	(63,836 )
Net cash provided by (used in) operating activities	1,762,520	(197,889 )
Cash flows from investing activities		
Investment in SAVSU	(6,000,000 )	—
Purchase of property and equipment	(339,068 )	(91,443 )
Net cash used in investing activities	(6,339,068 )	(91,443 )
Cash flows from financing activities		
Proceeds from private equity transaction	19,999,994	—
Proceeds from related party debt	—	1,000,000
Payments on equipment loan	(9,267 )	(10,628 )
Payments on capital lease obligations	(9,812 )	(7,631 )
Proceeds from exercise of common stock options and warrants	11,724,247	784,273
Payments of preferred stock dividends	(305,758 )	—
Payments of costs related to stock issuances	(42,500 )	(9,303 )

Edgar Filing: BIOLIFE SOLUTIONS INC - Form 10-Q

Payments for redemption of preferred stock	(1,063,000 )	—
Deferred costs related to potential stock issuance	—	(42,664 )
Net cash provided by financing activities	30,293,904	1,714,047
Net increase in cash and cash equivalents	25,717,356	1,424,715
Cash and cash equivalents - beginning of period	6,663,318	1,405,826
Cash and cash equivalents - end of period	\$32,380,674	\$2,830,541
Non-cash investing and financing activities		
Series A preferred stock dividends accrued not yet paid	\$79,675	\$106,250
Stock issued for services provided in prior period included in liabilities at year-end	35,625	35,624
Receivables converted to equity investment in SAVSU	150,103	—
Preferred stock issued on conversion of related party note payable and accrued interest	—	4,250,000
Capital lease obligations incurred for purchases of equipment	—	52,327
Purchase of equipment with debt	17,604	39,243
Legal fees for private equity transaction not yet paid	42,500	—
Purchase of property and equipment not yet paid	49,101	—

The accompanying Notes to Financial Statements are an integral part of these financial statements

Table of Contents**BioLife Solutions, Inc.****Statement of Shareholders' Equity****(unaudited)**

	<b>Preferred Stock Shares – Series A</b>	<b>Preferred Stock Amount – Series A</b>	<b>Common Stock Shares</b>	<b>Common Stock Amount</b>	<b>Additional Paid-in Capital</b>	<b>Accumulated Deficit</b>	<b>Total Shareholders' Equity</b>
Balance, December 31, 2017	4,250	\$ 4	14,021,422	\$ 14,021	\$ 84,036,444	\$(73,957,883 )	\$ 10,092,586
Redemption of preferred stock	(1,063 )	(1 )			(1,062,999 )		(1,063,000 )
Stock based compensation					1,130,945		1,130,945
Stock issued for private equity transaction, net of \$85,000 legal fees			1,428,571	1,429	19,913,565		19,914,994
Stock option/warrant exercises			2,684,899	2,684	11,721,563		11,724,247
Stock issued – on vested RSUs			96,594	97	(97 )		—
Stock issued for services			5,939	6	35,619		35,625
Preferred stock dividends						(279,183 )	(279,183 )
Net income						2,373,429	2,373,429
Balance, September 30, 2018	3,187	\$ 3	18,237,425	\$ 18,237	\$ 115,775,040	\$(71,863,637 )	\$ 43,929,643

The accompanying Notes to Financial Statements are an integral part of these financial statements

Table of Contents

**BIOLIFE SOLUTIONS, INC.**

**Notes to Financial Statements**

**(unaudited)**

**1. Organization and Significant Accounting Policies**

***Business***

BioLife Solutions, Inc. (“BioLife,” “us,” “we,” “our,” or the “Company”) is the leading developer, manufacturer and supplier of proprietary, clinical-grade biopreservation media for cells and tissues. Our HypoThermosol® hypothermic storage and CryoStor® cryopreservation freeze media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death; offering commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function.

***Basis of Presentation***

We have prepared the accompanying unaudited financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Pursuant to these rules and regulations, we have condensed or omitted certain information and footnote disclosures we normally include in our annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In management’s opinion, we have made all adjustments (consisting only of normal, recurring adjustments) necessary to fairly present our financial position, results of operations and cash flows. Our interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full year. These financial statements and accompanying notes should be read in conjunction with the financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2017 on file with the SEC.

There have been no material changes to our significant accounting policies as compared to the significant accounting policies described in the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2017, except the adoption of Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606).

*Significant Accounting Policies Update*

Revenue Recognition

On January 1, 2018, we adopted Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606) using the modified retrospective approach applied to those contracts in effect as of January 1, 2018. Under this transition method, results for reporting periods beginning after January 1, 2018 are presented under the new standard, while prior period amounts are not adjusted and continue to be reported in accordance with our historical accounting under Topic 605, Revenue Recognition. Adoption of the new standard did not have an impact on the amounts reported in our financial statements and there were no other significant changes impacting the timing or measurement of our revenue or our business processes and controls.

To determine revenue recognition for contractual arrangements that we determine are within the scope of Topic 606, we perform the following five steps: (i) identify each contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to our performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the relevant performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. Our revenues are primarily generated from the sale of our biopreservation media products. We generally recognize product revenue, including shipping and handling charges billed to customers, when we transfer control of our products to our customers as our contracts have a single performance obligation (transfer of control generally occurs upon shipment of our product). We are not required to disclose the value of unsatisfied performance obligations as our contracts have a duration of one year or less.

We invoice and receive payment from our customers after we recognize revenue, resulting in receivables from our customers that are presented as accounts receivable on our balance sheet. Accounts receivable consist of short-term amounts due from our customers (generally 30 to 90 days) and are stated at the amount we expect to collect. We establish an allowance for doubtful accounts based on our assessment of the collectability of specific customer accounts. Changes in accounts receivable are primarily due to the timing and magnitude of orders of our products, the timing of when control of our products is transferred to our customers and the timing of cash collections.

Table of Contents

***Equity Method Investments***

We account for our ownership in our SAVSU Technologies, Inc. joint venture (“SAVSU”) using the equity method of accounting. This method states that if the investment provides us the ability to exercise significant influence, but not control, over the investee, we account for the investment under the equity method. Significant influence is generally deemed to exist if the Company’s ownership interest in the voting stock of the investee ranges between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment is recorded at its initial carrying value in the balance sheet and is periodically adjusted for capital contributions, dividends received and our share of the investee’s earnings or losses together with other-than-temporary impairments which are recorded as a component of other income (expense), net in the statements of operations. On January 22, 2018, as a result of SAVSU signing a global distribution agreement with World Courier, we amended our agreement with SAVSU to fix our equity position at 35%, prior to any dilution created by financing activities post December 31, 2016, and terminated the sales and marketing services agreement. Our ownership in SAVSU was 35% at December 31, 2017. As a result of an additional \$6 million in cash contributions made by us and additional contributions made by the majority stockholder, our effective ownership was 44.4% at September 30, 2018. Additionally, we have an 18-month purchase option which provides us, at our sole discretion, with the right to acquire the 56% ownership interest of SAVSU not already owned, in exchange for the greater of 1,000,000 shares of our common stock, or approximately \$23 million of our common stock, calculated on the day of exercise. For the three and nine months ended September 30, 2018, SAVSU’s net loss totaled \$16,000 and \$1.1 million, respectively. For the three and nine months ended September 30, 2017, SAVSU’s net loss totaled \$0.5 million and \$1.6 million, respectively.

***Concentrations of credit risk and business risk***

In the three and nine months ended September 30, 2018, we derived approximately 41% of our product revenue from three customers and approximately 28% of our revenue from two customers, respectively. In the three and nine months ended September 30, 2017, we derived approximately 22% of our product revenue from two customers and 10% of our product revenue from one customer, respectively. No other customer accounted for more than 10% of revenue in the three and nine months ended September 30, 2018 or 2017. At September 30, 2018, four customers accounted for approximately 54% of total gross accounts receivable. At December 31, 2017, two customers accounted for approximately 41% of total gross accounts receivable.

Revenue from customers located in foreign countries represented 8% and 10% of total revenue during the three and nine months ended September 30, 2018, respectively, and 16% and 17% during the three and nine months ended September 30, 2017, respectively. All revenue from foreign customers is denominated in United States dollars.

***Recent Accounting Pronouncements***

In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (ASU 2016-15). The updated guidance clarifies how companies present and classify certain cash receipts and cash payments in the statement of cash flows. We adopted the new standard on January 1, 2018, with no material impact on our financial statements.

In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases: Topic 842 (ASU 2016-02) that replaces existing lease guidance. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. Under the new guidance, leases will continue to be classified as either finance or operating, with classification affecting the pattern of expense recognition in the Statements of Operations. Lessor accounting is largely unchanged under ASU 2016-02. The new guidance will be effective for fiscal years and interim periods within those years beginning after December 15, 2018. Early adoption will be permitted for all entities. The Company will adopt ASU 2016-02 on January 1, 2019.

The FASB has issued several additional ASUs that provide additional clarification to certain issues existing after the original ASU was released. In July 2018, the FASB issued ASU 2018-11 Leases (Topic 842) Targeted Improvements which provides entities with an additional and optional transition method to adopt the new lease standard and provide lessors with a practical expedient, by class of underlying asset, to not separate non-lease components from the associated lease component and, instead, to account for those components as a single component if certain criteria are met. Also, in July 2018, the FASB issued ASU 2018-10 Codification Improvements to Topic 842 to make amendments addressing sixteen issues related to various aspects of ASU 2016-02. The effective date and transition requirements for the amendments in ASU 2018-11 and ASU 2018-10 will be the same as the effective date and transition requirements in ASU 2016-02. The Company is evaluating the effect of ASU 2018-11 and ASU 2018-10 on its financial statements. While the Company is continuing to evaluate the effects of this ASU, the Company expects to record material right of use assets and lease liabilities on its balance sheet upon adoption. The new standard will also require expanded qualitative and quantitative disclosures regarding the Company’s leases.

In January 2016, the FASB issued Accounting Standards Update No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities: Topic 825 (ASU 2016-01). The updated guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. We adopted the new standard on January 1, 2018, with no material impact on our financial statements.

With the exception of the new standards discussed above, there have been no new accounting pronouncements not yet effective that have significance, or potential significance, to our Financial Statements.



Table of Contents**2.Fair Value Measurement**

In accordance with FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” (“ASC Topic 820”), the Company measures its cash and cash equivalents and short-term investments at fair value on a recurring basis. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC Topic 820 establishes a three-tier value fair hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1 – Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than quoted prices included in Level 1 for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3 – Unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.

As of September 30, 2018 and December 31, 2017, the Company does not have liabilities that are measured at fair value.

The following tables set forth the Company’s financial assets measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2017, based on the three-tier fair value hierarchy:

<b>As of September 30, 2018</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Total</b>
Bank deposits	\$32,327,287	\$	—\$32,327,287
Money market funds	53,387		— 53,387
Total cash and cash equivalents	\$32,380,674	\$	—\$32,380,674

<b>As of December 31, 2017</b>	<b>Level 1</b>	<b>Total</b>
--------------------------------	----------------	--------------

		<b>Level</b>	
		<b>2</b>	
Bank deposits	\$6,610,183	\$	—\$6,610,183
Money market funds	53,135		— 53,135
Total cash and cash equivalents	\$6,663,318	\$	—\$6,663,318

The fair values of bank deposits and money market funds classified as Level 1 were derived from quoted market prices as active markets for these instruments exist. The Company has no level 2 or level 3 financial assets. The Company did not have any transfers between Level 1 and Level 2 of the fair value hierarchy during the nine months ended September 30, 2018 and the twelve months ended December 31, 2017.

Table of Contents**3.Inventory**

Inventory consists of the following at September 30, 2018 and December 31, 2017:

	<b>September 30,  2018</b>	<b>December 31,  2017</b>
Raw materials	\$1,168,969	\$582,816
Work in progress	830,991	453,890
Finished goods	910,967	810,040
Total	\$2,910,927	\$1,846,746

**4.Deferred Rent**

Deferred rent consists of the following at September 30, 2018 and December 31, 2017:

	<b>September 30,  2018</b>	<b>December 31,  2017</b>
Landlord-funded leasehold improvements	\$1,124,790	\$1,124,790
Less accumulated amortization	(724,773 )	(629,525 )
Total	400,017	495,265
Straight line rent adjustment	116,312	127,158
Total deferred rent	\$516,329	\$622,423

During the three and nine month periods ended September 30, 2018, the Company recorded \$31,749 and \$95,248, respectively, in deferred rent amortization of these landlord funded leasehold improvements. During the three and nine month periods ended September 30, 2017, the Company recorded \$31,749 and \$95,249, respectively, in deferred rent amortization of these landlord funded leasehold improvements.

Straight line rent adjustment represents the difference between cash rent payments and the recognition of rent expense on a straight-line basis over the terms of the lease.

## 5.Share-based Compensation

### *Service Vesting-Based Stock Options*

The following is a summary of service vesting-based related stock option activity for the nine month period ended September 30, 2018, and the status of service vesting-based options outstanding at September 30, 2018:

	<b>Nine Month Period Ended September 30, 2018</b>	
	<b>Options</b>	<b>Wtd. Avg. Exercise Price</b>
Outstanding at beginning of year	2,390,012	\$ 1.85
Granted	—	\$ —
Exercised	(267,055 )	\$ 1.30
Forfeited	(15,627 )	\$ 4.34
Expired	—	\$ —
Outstanding service vesting-based at September 30, 2018	2,107,330	\$ 1.90
Service vesting-based options exercisable at September 30, 2018	1,622,980	\$ 1.83

We recognized stock compensation expense related to service vesting-based options of \$146,567 and \$146,355 during the three months ended September 30, 2018 and 2017, respectively, and \$448,882 and \$463,217 during the nine months ended September 30, 2018 and September 30, 2017, respectively. As of September 30, 2018, there was \$32,868,498 of aggregate intrinsic value of outstanding service vesting-based stock options, including \$25,429,311 of aggregate intrinsic value of exercisable service vesting-based stock options. Intrinsic value is the total pretax intrinsic value for all “in-the-money” options (i.e., the difference between the Company’s closing stock price on the last trading day of the quarter and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all option holders exercised their options on September 30, 2018. This amount will change based on the fair market value of the Company’s stock. Intrinsic value of service vesting-based awards exercised during the three months ended September 30, 2018 and 2017 was \$2,094,344 and none, respectively, and during the nine months ended September 30, 2018 and 2017 was \$3,088,117 and \$91,817, respectively. Weighted average grant date fair value for service based-vesting options granted during the three months ended September 30, 2018 and 2017 was none and for the nine months ended September 30, 2018 and 2017 was none and \$1.13 per share, respectively. The weighted average remaining contractual life of service vesting-based options outstanding and exercisable at

September 30, 2018, is 5.8 years and 5.5 years, respectively. Total unrecognized compensation cost of service vesting-based stock options at September 30, 2018 of \$678,908 is expected to be recognized over a weighted average period of 1.6 years.

Table of Contents***Performance-based Stock Options***

The Company's Board of Directors implemented a Management Performance Bonus Plan for 2017. Based on achieving varying levels of specified revenue for the year ended December 31, 2017, up to 1,000,000 options to purchase shares of the Company's common stock may be vested. The options have an exercise price of \$1.64, and if revenue levels for 2017 were met, would vest 50% on the release of the Company's audited financial statements for 2017, and 50% one year thereafter. If the minimum performance targets were not achieved, no options would vest. On February 27, 2018, the Company's Board of Directors determined that, subject to the completion of the 2017 audit, the specified revenue target had been achieved. Accordingly, 999,997 options to purchase shares of the Company's common stock vest as follows: 50% of the options vested on March 8, 2018 and the remaining 50% will vest on March 8, 2019.

The following is a summary of performance-based stock option activity for the nine month period ended September 30, 2018, and the status of performance-based options outstanding at September 30, 2018:

	<b>Nine Month Period Ended September 30, 2018</b>	
	<b>Options</b>	<b>Wtd. Avg. Exercise Price</b>
Outstanding at beginning of year	999,997	\$ 1.64
Granted	—	\$ —
Exercised	(35,000 )	\$ 1.64
Outstanding performance-based at September 30, 2018	964,997	\$ 1.64
Performance-based options exercisable at September 30, 2018	465,001	\$ 1.64

We recognized stock compensation expense related to performance-based options of \$128,296 and \$128,298 during the three month periods ending September 30, 2018 and 2017, respectively, and \$380,705 and \$380,708 during the nine month periods ending September 30, 2018 and 2017, respectively. As of September 30, 2018, there was \$15,304,852 of aggregate intrinsic value of outstanding performance-based stock options, including \$7,374,916 of aggregate intrinsic value of exercisable performance-based stock options. Intrinsic value is the total pretax intrinsic value for all "in-the-money" options (i.e., the difference between the Company's closing stock price on the last trading day of the quarter and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all option holders exercised their options on September 30, 2018. This amount will change based on the fair market value of the Company's stock. Intrinsic value of performance-based awards exercised during the

three months and nine months ended September 30, 2018 was none and \$285,250, respectively, and no performance-based options were exercised in the three and nine months ended September 30, 2017. The weighted average remaining contractual life of performance-based options outstanding and exercisable at September 30, 2018, is 3.2 years. Total unrecognized compensation cost of performance-based stock options at September 30, 2018 of \$128,296 is expected to be recognized over a weighted average period of 0.3 years.

Table of Contents

The fair value of share-based payments made with stock options to employees and non-employee directors was estimated on the measurement date using the Black-Scholes model using the following weighted average assumptions.

	<b>Three Month Period Ended September 30, 2018</b>		<b>Nine Month Period Ended September 30, 2017</b>	
Risk free interest rate	N/A	N/A	N/A	2.07 %
Dividend yield	N/A	N/A	N/A	0.0 %
Expected term (in years)	N/A	N/A	N/A	5.18
Volatility	N/A	N/A	N/A	75 %

***Restricted Stock***

The following is a summary of restricted stock activity for the nine month period ended September 30, 2018, and the status of unvested restricted stock outstanding at September 30, 2018:

	<b>Nine Month Period Ended September 30, 2018 Number of Grant-Date Restricted Fair Value Shares</b>	
Outstanding at beginning of year	237,926	\$ 1.79
Granted	181,268	\$ 7.02
Vested	(96,593 )	\$ 1.80
Forfeited	(21,128 )	\$ 3.32
Outstanding at September 30, 2018	301,473	\$ 4.82

The aggregate fair value of the awards granted during the three and nine months ended September 30, 2018 was \$147,900 and \$1,272,948, respectively, and during the three and nine months ended September 30, 2017 was none and \$364,936, respectively, which represents the market value of our common stock on the date that the restricted stock awards were granted. The aggregate fair value of the restricted stock awards that vested for the three months ended September 30, 2018 and 2017 was \$392,858 and \$38,567, respectively, and for the nine months ended September 30, 2018 and 2017 was \$873,594 and \$99,725, respectively.



We recognized stock compensation expense of \$108,277 and \$39,290 related to restricted stock awards for the three months ended September 30, 2018 and 2017, respectively, and \$301,058 and \$113,786 related to restricted stock awards for the nine months ended September 30, 2018 and 2017, respectively. As of September 30, 2018, there was \$1,245,763 in unrecognized compensation costs related to restricted stock awards. We expect to recognize those costs over 3.2 years.

We recorded total stock compensation expense for the three and nine month periods ended September 30, 2018 and 2017, as follows:

	<b>Three Month Period Ended September 30, 2018      2017</b>		<b>Nine Month Period Ended September 30, 2018      2017</b>	
Research and development costs	\$64,970	\$59,434	\$195,316	\$177,514
Sales and marketing costs	64,152	55,402	201,907	173,072
General and administrative costs	194,764	156,621	576,718	479,803
Cost of product sales	59,254	42,486	157,004	127,322
Total	\$383,140	\$313,943	\$1,130,945	\$957,711

Table of Contents

**6. Warrants**

At September 30, 2018 and December 31, 2017, we had 4,306,005 and 6,688,849 warrants outstanding, respectively, and exercisable with a weighted average exercise price of \$4.37 and \$4.50, respectively. During the three and nine month period ended September 30, 2018, 557,153 and 2,382,844 warrants were exercised with a weighted average exercise price of \$4.75, yielding proceeds of \$2.6 million and \$11.3 million, respectively. Subsequent to quarter end through November 7, 2018, an additional 225,000 warrants were exercised with a weighted average exercise price of \$4.75, yielding \$1.1 million in proceeds to the Company. The outstanding warrants have expiration dates between March 2021 and May 2021.

**7. Income Taxes**

We have recorded a full valuation allowance against our deferred tax assets. As we trend towards positive net income, we will continue to assess our valuation allowance. Based on all available evidence, we determined that we have not yet attained a sustained level of profitability. Therefore, we have maintained the full valuation allowance at September 30, 2018. We may release all, or a portion, of the valuation allowance in the near-term, dependent on the verifiable positive evidence observed in future quarters.

**8. Earnings Per Share**

Basic earnings per share is calculated by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated using the weighted average number of common shares outstanding plus dilutive common stock equivalents outstanding as determined by the treasury method during the period. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect. For the three and nine month periods ended September 30, 2018, we excluded a nominal amount of unvested stock awards from our calculation of diluted weighted average shares because they were antidilutive. For the three and nine month periods ended September 30, 2017, we excluded 3.4 million common stock options, 7.4 million warrants, and 259,000 unvested stock awards from our calculation of diluted weighted average shares because they were antidilutive.

The following table shows the calculation of basic and diluted earnings per shares:

	<b>Three Month Period Ended September 30, 2018</b>		<b>Nine Month Period Ended September 30, 2018</b>	
	<b>2017</b>		<b>2017</b>	
Numerator:				
Net income (loss) attributable to common stockholders	\$ 1,151,094	\$(424,968 )	\$ 2,094,246	\$(2,063,470 )
Denominator:				
Weighted average basic shares outstanding	17,273,412	13,238,248	15,529,026	13,102,238
Effect of dilutive securities	6,383,221	—	5,522,193	—
Weighted average diluted shares	23,656,633	13,238,248	21,051,219	13,102,238
Basic earnings per share	\$0.07	\$(0.03 )	\$0.13	\$(0.16 )
Diluted earnings per share	\$0.05	\$(0.03 )	\$0.10	\$(0.16 )

## 9. Commitments & Contingencies

### *Leases*

We lease approximately 30,000 square feet in our Bothell, Washington headquarters. The term of our lease continues until July 31, 2021 with two options to extend the term of the lease, each of which is for an additional period of five years, with the first extension term commencing, if at all, on August 1, 2021, and the second extension term commencing, if at all, immediately following the expiration of the first extension term. In accordance with the amended lease agreement, our monthly base rent is approximately \$59,000 at September 30, 2018, with scheduled annual increases each August and again in October for the most recent amendment. We are also required to pay an amount equal to the Company's proportionate share of certain taxes and operating expenses.

### *Employment Agreements*

We have employment agreements with our Chief Executive Officer, Chief Financial Officer, Chief Technology Officer, Vice President of Operations, Vice President of Marketing, and Vice President of Sales. None of these employment agreements is for a definitive period, but rather each will continue indefinitely until terminated in accordance with its terms. The agreements provide for a base annual salary, payable in monthly (or shorter) installments. Under certain conditions and for certain of these officers, we may be required to pay additional amounts upon terminating the officer or upon the officer resigning for good reason.



Table of Contents*Litigation*

From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none of which are currently material to the Company's business.

**10. Preferred Stock**

As of September 30, 2018, we accrued a dividend of \$79,675 on the series A preferred stock which is included in accrued expenses and other current liabilities in the balance sheet at September 30, 2018. The dividend was paid subsequent to quarter end on October 1, 2018. There are 3,187 Series A shares outstanding as of September 30, 2018.

**11. Revenue**

We currently operate as one operating segment focusing on biopreservation media.

The following table disaggregates revenue by market segment and distributors:

	<b>Three Month Period Ended September 30, 2018</b>		<b>Nine Month Period Ended September 30, 2018</b>	
	<b>2018</b>	<b>2017</b>	<b>2018</b>	<b>2017</b>
Net product sales:				
Regenerative medicine	\$2,875,861	\$1,599,916	\$7,964,499	\$3,734,724
Distributors	1,886,885	759,826	4,621,280	2,213,880
Drug discovery	275,747	320,206	915,745	1,087,014
BioBanking	254,582	283,463	784,287	851,759
Total	\$5,293,075	\$2,963,411	\$14,285,811	\$7,887,377



Table of Contents

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

***Forward Looking Statements***

This Quarterly Report on Form 10-Q contains "forward-looking statements". These forward-looking statements involve a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. These statements are based on current expectations of future events. Such statements include, but are not limited to, statements about future financial and operating results, plans, objectives, expectations and intentions, costs and expenses, interest rates, outcome of contingencies, financial condition, results of operations, liquidity, business strategies, cost savings, objectives of management and other statements that are not historical facts. You can find many of these statements by looking for words like "believes," "expects," "anticipates," "estimates," "may," "should," "will," "plan," "intend," or similar expressions in this Quarterly Report on Form 10-Q. We intend that such forward-looking statements be subject to the safe harbors created thereby. Examples of these forward-looking statements include, but are not limited to:

anticipated product developments, customer regulatory filings and related requirements;

timing and amount of future contractual payments, product revenue and operating expenses;

market acceptance of our products and the estimated potential size of these markets; and

projections regarding liquidity, capital requirements and the terms of any financing agreements.

These forward-looking statements are based on the current beliefs and expectations of our management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results may differ materially from current expectations and projections. These risks and uncertainties include those factors described in greater detail in the risk factors disclosed in our Form 10-K for the fiscal year ended December 31, 2017 filed with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those anticipated in these forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q or, in the case of documents referred to or incorporated by reference, the date of those documents.

All subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events, except as may be required under applicable U.S. securities law. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

## Overview

Management's discussion and analysis provides additional insight into the Company and is provided as a supplement to, and should be read in conjunction with, our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed with the SEC.

We were incorporated in Delaware in 1987 under the name Trans Time Medical Products, Inc. In 2002, the Company, then known as Cryomedical Sciences, Inc., and engaged in manufacturing and marketing cryosurgical products, completed a merger with our wholly-owned subsidiary, BioLife Solutions, Inc., which was engaged as a developer and marketer of biopreservation media products for cells and tissues. Following the merger, we changed our name to BioLife Solutions, Inc.

Our proprietary, clinical grade HypoThermosol® FRS and CryoStor® biopreservation media products are marketed to the regenerative medicine, biobanking and drug discovery markets, including hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, hair transplant centers, and suppliers of cells to the drug discovery, toxicology testing and diagnostic markets. All of our biopreservation media products are serum-free and protein-free, fully defined, and are manufactured under current Good Manufacturing Practices (cGMP). We strive to use United States Pharmacopia (USP)/Multicompidual or the highest available grade components.



## Table of Contents

Our patented biopreservation media products are formulated to reduce preservation-induced, delayed-onset cell damage and death. Our platform enabling technology provides our customers significant shelf life extension of biologic source material and final cell products, and also greatly improved post-preservation cell, tissue, and organ viability and function.

The discoveries made by our scientists and consultants relate to how cells, tissues, and organs respond to the stress of hypothermic storage, cryopreservation, and the thawing process. These discoveries enabled the formulation of innovative biopreservation media products that protect biologic material from preservation-related cellular injury, much of which is not apparent immediately after return to normothermic body temperature. Our product formulations have demonstrated notable reduction in apoptotic (programmed) and necrotic (pathologic) cell death mechanisms and are enabling the clinical and commercial development of dozens of innovative regenerative medicine products.

Additionally, as of September 30, 2018, we owned a 44.4% interest in our joint venture, SAVSU Technologies, Inc. (“SAVSU”), a Delaware corporation. Our ownership in SAVSU was 35% at December 31, 2017. As a result of an additional \$6 million in cash contributions made by us and additional contributions made by the majority stockholder, our effective ownership was 44.4% at September 30, 2018. We have an 18-month purchase option which provides us, at our sole discretion, with the right to acquire the 56% ownership interest of SAVSU not already owned, in exchange for the greater of 1,000,000 shares of our common stock, or approximately \$23 million of our common stock, calculated on the day of exercise. SAVSU is a privately held designer and manufacturer of innovative high-performance cloud-connected passive storage and transport containers for temperature sensitive biologics and pharmaceuticals. SAVSU’s mission is to improve global health by greatly reducing the waste and risks associated with the improper freezing and overheating of thermal-sensitive medicines and biologics. SAVSU has developed proprietary state-of-the-art technology to ultimately lower costs and improve delivery of these most essential materials.

## *Highlights for the Third Quarter of 2018*

Revenue was \$5.3 million in the third quarter of 2018, an increase of 79% over the same period in 2017. For the first nine months of 2018, revenue increased 81% as compared to the same period last year. Third quarter revenue growth was primarily driven by a 80% increase in direct sales to our regenerative medicine customers and a 148% growth from our distributors compared to the same period in 2017.

Gross margin in the third quarter of 2018 was 70%, compared to 63% in the third quarter of 2017. For the first nine months of 2018 gross margin was 68% compared to 62% in the first nine months of 2017. The margin increased due to higher average selling price per liter and increased sales volume.

Operating income for the three and nine months ended September 30, 2018 was \$1.2 million and \$2.6 million, respectively, compared to an operating loss of \$32,000 and \$0.8 million for the three and nine months ended September 30, 2017, respectively. We were able to generate operating income due to the increase in sales and gross margin from the same period in the prior year.

In the three and nine months ended September 30, 2018, net income attributable to common stockholders was \$1.2 million and \$2.1 million, respectively. This compared to a net loss attributable to common stockholders of \$0.4

million and \$2.1 million for the three and nine months ended September 30, 2017, respectively. We were able to generate a net profit due to the increase in sales and gross margin from the same period in the prior year.

Gained 25 new customers in the third quarter of 2018, including first time orders from 15 regenerative medicine companies.

Increased ownership in SAVSU Technologies from approximately 31% to 44% with a \$5 million investment.

SAVSU will use the investment to scale up its operations and inventory to support increased demand for its evo® Dry Vapor Shippers and other precision temperature controlled shipping containers for cell and gene therapies.

Casdin Capital LLC, a New York-based, life science-focused investment firm and current stockholder of the Company, invested \$20 million in the Company to support the Company's growth strategy of acquiring synergistic cell and gene therapy manufacturing tools and services or technologies.

Two funds managed by Sandler Capital Management, a New York-based, sophisticated investor, active in the life science tools and services space, purchased 500,000 shares of Company common stock in a private transaction with the Company's two largest shareholders.

Table of Contents**Results of Operations**

Our revenue, results of operations and cash balances are likely to fluctuate significantly from quarter-to-quarter. These fluctuations are due to a number of factors, specifically the progress of our customers' clinical trials, where the pace of enrollment affects customer orders for our products. The majority of our net sales come from a relatively small number of customers and a limited number of market sectors. Each of these sectors is subject to macroeconomic conditions as well as trends and conditions that are sector specific. Any weakness in the market sectors in which our customers are concentrated could affect our business and results of operations.

***Comparison of Results of Operations for the Three and Nine Month Periods Ended September 30, 2018 and 2017***

Percentage comparisons have been omitted within the following table where they are not considered meaningful.

***Revenue and Gross Margin:***

	<b>Three Month Period Ended September 30,</b>			
	<b>2018</b>	<b>2017</b>	<b>% Change</b>	
Revenue:				
Total revenue	\$5,293,075	\$2,963,411	79	%
Cost of sales	1,606,303	1,095,724	47	%
Gross profit	\$3,686,772	\$1,867,687	97	%
Gross margin %	70	% 63	%	

	<b>Nine Month Period Ended September 30,</b>			
	<b>2018</b>	<b>2017</b>	<b>% Change</b>	
Revenue:				
Total revenue	\$14,285,811	\$7,887,377	81	%
Cost of sales	4,506,911	2,980,965	51	%
Gross profit	\$9,778,900	\$4,906,412	99	%

Gross margin % 68 % 62 %

*Biopreservation Media Product Sales.* Our core products are sold through both direct and indirect channels to customers in the regenerative medicine, biobanking and drug discovery markets. Sales of our core products in the three and nine months ended September 30, 2018 increased 79% and 81%, respectively, compared to the same periods in 2017, due primarily to an increase in volume and selling price per liter sold due to increased orders from the regenerative medicine segment and our distributors. Revenue growth for the third quarter was driven by an 80% year over year increase from customers in the regenerative medicine segment and 148% growth from sales to our distributors. We expect to see continued growth in adoption and use of our proprietary biopreservation media products.

*Cost of Sales.* Cost of sales consists of raw materials, labor and overhead expenses. Cost of sales in the three and nine months ended September 30, 2018 increased compared to the same periods in 2017 due to increased sales of our proprietary products partially offset by lower overhead costs per liter sold in the three and nine months ended September 30, 2018.

*Gross Margin.* Gross margin as a percentage of revenue in the three and nine months ended September 30, 2018 was 70% and 68%, respectively, compared to 63% and 62% in the three and nine months ended September 30, 2017, respectively. Gross margin in the three and nine months ended September 30, 2018 increased compared to the same periods in 2017 due to increased average selling price per liter sold and lower overhead costs per liter sold resulting in higher production volume to support increased demand in the three and nine months ended September 30, 2018.

Table of Contents

**Revenue Concentration.** In the three and nine months ended September 30, 2018, we derived approximately 41% of our product revenue from three customers and approximately 28% of our revenue from two customers, respectively. In the three and nine months ended September 30, 2017, we derived approximately 22% of our product revenue from two customers and 10% of our product revenue from one customer, respectively. No other customer accounted for more than 10% of revenue in the three and nine months ended September 30, 2018 or 2017.

**Operating Expenses**

Our operating expenses for the three and nine month periods ended September 30, 2018 and 2017 were:

	<b>Three Month Period Ended September 30,</b>			
	<b>2018</b>	<b>2017</b>	<b>% Change</b>	
Operating Expenses:				
Research and development	\$312,000	\$293,093	6	%
Sales and marketing	725,201	488,688	48	%
General and administrative	1,454,573	1,118,251	30	%
Operating Expenses	\$2,491,774	\$1,900,032	31	%
% of revenue	47	% 64	%	

	<b>Nine Month Period Ended September 30,</b>			
	<b>2018</b>	<b>2017</b>	<b>% Change</b>	
Operating Expenses:				
Research and development	\$983,066	\$898,451	9	%
Sales and marketing	1,977,871	1,547,087	28	%
General and administrative	4,198,474	3,298,461	27	%
Operating Expenses	\$7,159,411	\$5,743,999	25	%
% of revenue	50	% 73	%	

**Research and Development.** Research and development expenses consist primarily of salaries and other personnel-related expenses, consulting and other outside services, laboratory supplies, and other costs. We expense all research and development costs as incurred. Research and development expenses for the three and nine months ended September 30, 2018 increased compared to the three and nine months ended September 30, 2017, due primarily to higher performance-based compensation.

*Sales and Marketing.* Sales and marketing expenses consist primarily of salaries and other personnel-related expenses, consulting, trade shows and advertising. Sales and marketing expenses for the three and nine months ended September 30, 2018 increased compared to the three and nine months ended September 30, 2017, due primarily to higher performance-based compensation, tradeshow, travel and market research.

*General and Administrative Expenses.* General and administrative expenses consist primarily of personnel-related expenses, non-cash stock-based compensation for administrative personnel and members of the board of directors, professional fees, such as accounting and legal, and corporate insurance. General and administrative expenses for the three months ended September 30, 2018 increased compared to the three months ended September 30, 2017, due primarily to higher performance-based compensation and legal fees. General and administrative expenses for the nine months ended September 30, 2018 increased compared to the nine months ended September 30, 2017, due primarily to increased investor relations, travel and consulting fees, quality system consulting fees, higher performance-based compensation and corporate non-income taxes.

#### ***Other Income (Expenses)***

*Interest Expense.* The interest expense in the three and nine months ended September 30, 2018 is due to equipment financing. Interest expense in the nine months ended September 30, 2017 is due to the note payable related to the credit facility financing arrangement entered into in May 2016 which was converted to preferred stock in 2017.

*Amortization of debt discount.* The amortization of short-term debt discount in the nine months ended September 30, 2017 is due to the amortization of the allocated value of the detachable warrants associated with the credit facility financing on arrangement entered into in May 2017 which was fully amortized May 31, 2017.

*Loss on equity method investment.* The non-cash loss associated with our proportionate share of the net loss in our investment in SAVSU.

*Interest income.* The increase in interest income in the three and nine months ended September 30, 2018 compared to the same periods in 2017 is due to the higher average short-term liquid investments balance in 2018 compared to 2017.

Table of Contents

**Liquidity and Capital Resources**

On September 30, 2018, we had \$32.4 million in cash and cash equivalents, compared to cash and cash equivalents of \$6.7 million at December 31, 2017. In August 2018, Casdin Capital purchased \$20.0 million of our common stock in a private transaction. During the nine month period ended September 30, 2018, 2.4 million warrants were exercised with a weighted average exercise price of \$4.75, yielding \$11.3 million in proceeds to the Company. We currently have an S-3 registration statement filed with the SEC which may be utilized to obtain additional financing.

We continue to monitor and evaluate opportunities to strengthen our balance sheet and competitive position over the long term. These actions may include acquisitions or other strategic transactions that we believe would generate significant advantages and substantially strengthen our business. The consideration we pay in such transactions may include, among other things, shares of our common stock, other equity or debt securities of our Company or cash. We may elect to seek debt or equity financing in anticipation of, or in connection with, such transactions or to fund or invest in any operations acquired thereby.

***Net Cash Provided by/ Used In Operating Activities***

During the nine months ended September 30, 2018, net cash provided by operating activities was \$1.8 million compared to net cash used in operating activities of \$0.2 million for the nine months ended September 30, 2017. The increase in cash from operating activities was the result of increased sales and gross margins partially offset by an increase in accounts receivable and inventory from the prior period.

***Net Cash Used In Investing Activities***

Net cash used in investing activities totaled \$6.3 million during the nine months ended September 30, 2018, compared to \$91,000 for the nine months ended September 30, 2017. The increase in cash used by investing activities was primarily the result of the additional investments in SAVSU.

***Net Cash Provided by Financing Activities***

Net cash provided by financing activities was \$30.3 million and \$1.7 million in the nine months ended September 30, 2018 and 2017, respectively. Net cash provided by financing activities during the nine months ended September 30,

2018 was primarily the result of proceeds received from a private equity transaction with Casdin Capital as well as warrant exercises and employee stock option exercises. Net cash provided by financing activities in the nine months ended September 30, 2017 was the result of proceeds received from our credit facility, warrant exercises and employee stock option exercises.

### **Off-Balance Sheet Arrangements**

As of September 30, 2018, we did not have any off-balance sheet arrangements.

### **Critical Accounting Policies and Significant Judgments and Estimates**

Management's discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate estimates, including, but not limited to those related to accounts receivable allowances, determination of fair value of share-based compensation, contingencies, income taxes, and expense accruals. We base our estimates on historical experience and on other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.

Our critical accounting policies and estimates have not changed significantly from those policies and estimates disclosed under the heading "Critical Accounting Policies and Significant Judgments and Estimates" in Part II, Item 7, "Management's Discussion and Analysis of Financial Conditions and Results of Operations" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the SEC.



Table of Contents

**Contractual Obligations**

We previously disclosed certain contractual obligations and contingencies and commitments relevant to us within the financial statements and Management Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the SEC on March 9, 2018. There have been no significant changes to these obligations in the three months ended September 30, 2018. For more information regarding our current contingencies and commitments, see note 9 to the financial statements included above.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

*Not applicable.*

**Item 4. Controls and Procedures**

*Evaluation of Disclosure Controls and Procedures.* We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and to ensure that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer as appropriate, to allow timely decisions regarding required disclosure. During the quarter ended September 30, 2018, we carried out an evaluation, under the supervision and with the participation of our management, including the chief executive officer and chief financial officer, as required by the rules and regulations under the Exchange Act, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of September 30, 2018, our disclosure controls and procedures were effective.

*Changes in Internal Control over Financial Reporting.* There have been no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2018 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

*Limitations on Effectiveness of Control.* Our management, including our chief executive officer and chief financial officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative

to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected.

## **PART II: Other Information**

### **Item 6. Exhibits**

20

---

Table of Contents

**BioLife Solutions, Inc.**

**INDEX TO EXHIBITS**

**Exhibit No. Description**

31.1	<u>Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u>
31.2	<u>Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u>
32.1	<u>Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u>
32.2	<u>Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u>
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema
101.CAL	XBRL Taxonomy Extension Calculation Linkbase
101.DEF	XBRL Taxonomy Extension Definition Linkbase
101.LAB	XBRL Taxonomy Extension Label Linkbase
101.PRE	XBRL Taxonomy Extension Presentation Linkbase

Table of Contents

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BIOLIFE SOLUTIONS, INC.**

Dated: November 8, 2018 /s/ Roderick de Greef  
Roderick de Greef  
Chief Financial Officer  
(Duly authorized officer and principal financial and accounting officer)